Effects of deracoxib and aspirin on serum concentrations of thyroxine, 3,5,3′-triiodothyronine, free thyroxine, and thyroid-stimulating hormone in healthy dogs

AbstractThyroid hormone reference intervals are crucial for diagnosing and monitoring thyroid dysfunction during early pregnancy, and the dynamic change trend of thyroid hormones during pregnancy can assist clinicians to assess the thyroid function of pregnant women. This study aims to establish early pregnancy related thyroid hormones models and reference intervals for pregnant women. We established two derived databases: derived database* and derived database#. Reference individuals in database* were used to establish gestational age-specific reference intervals for thyroid hormones and early pregnancy related thyroid hormones models for pregnant women. Individuals in database# were apparently healthy non-pregnant women. The thyroid hormones levels of individuals in database# were compared with that of individuals in database* using nonparametric methods and the comparative confidence interval method. The differences in thyroid stimulating hormone and free thyroxine between early pregnant and non-pregnant women were statistically significant (p<0.0001). The reference intervals of thyroid stimulating hormone, free thyroxine and free triiodothyronine for early pregnant women were 0.052–3.393 μIU/ml, 1.01–1.54 ng/dl, and 2.51–3.66 pg/ml, respectively. Results concerning thyroid stimulating hormone and free thyroxine reference intervals of early pregnancy are comparable with those from other studies using the same detection platform. Early pregnancy related thyroid hormones models showed various change patterns with gestational age for thyroid hormones. Early pregnancy related thyroid hormones models and reference intervals for pregnant women were established, so as to provide accurate and reliable reference basis for the diagnosing and monitoring of maternal thyroid disfunction in early pregnancy.

Download Full-text

Method specific second-trimester reference intervals for thyroid-stimulating hormone and free thyroxine

Clinical Biochemistry ◽

10.1016/j.clinbiochem.2008.12.004 ◽

2009 ◽

Vol 42 (7-8) ◽

pp. 750-753 ◽

Cited By ~ 16

Author(s):

Rechelle Silvio ◽

Karly J. Swapp ◽

Sonia L. La'ulu ◽

Kara Hansen-Suchy ◽

William L. Roberts

Keyword(s):

Reference Intervals ◽

Thyroid Stimulating Hormone ◽

Free Thyroxine ◽

Second Trimester ◽

Stimulating Hormone

Download Full-text

Preterm to term infant postmenstrual age reference intervals for thyroid-stimulating hormone and free thyroxine

Pediatric Research ◽

10.1038/s41390-021-01838-3 ◽

2021 ◽

Author(s):

George M. Ziegler ◽

Jonathan L. Slaughter ◽

Monika Chaudhari ◽

Herveen Singh ◽

Pablo J. Sánchez ◽

...

Keyword(s):

Reference Intervals ◽

Thyroid Stimulating Hormone ◽

Term Infant ◽

Free Thyroxine ◽

Postmenstrual Age ◽

Stimulating Hormone

Download Full-text

Sex-specific genetic influence on thyroid-stimulating hormone and free thyroxine levels, and interactions between measurements: KNHANES 2013–2015

PLoS ONE ◽

10.1371/journal.pone.0207446 ◽

2018 ◽

Vol 13 (11) ◽

pp. e0207446 ◽

Cited By ~ 5

Author(s):

Young Ki Lee ◽

Dong Yeob Shin ◽

Hyejung Shin ◽

Eun Jig Lee

Keyword(s):

Thyroid Stimulating Hormone ◽

Free Thyroxine ◽

Genetic Influence ◽

Stimulating Hormone

Download Full-text

Subclinical Hyperthyroidism: Diagnostic Criteria and Principles of Treatment

Family Medicine ◽

10.30841/2307-5112.5.2016.248750 ◽

2016 ◽

pp. 75-79

Author(s):

Vita Galitskaya

Keyword(s):

Hormone Receptors ◽

Color Doppler ◽

Specific Treatment ◽

Nodular Goiter ◽

Thyroid Stimulating Hormone ◽

Free Thyroxine ◽

Subclinical Hyperthyroidism ◽

Mineral Density ◽

Free Triiodothyronine ◽

Stimulating Hormone

This article presents the European Thyroid Association guidelines for diagnosis and treatment of subclinical hyperthyroidism, 2015. Determination of thyroid1stimulating hormone levels can help to diagnose a variety of pathological conditions: hypertension, cardiac fibrillation, atrial fibrillation, mineral density reduction in bones, menstrual irregularities, infertility, which require specific treatment after detection of hormonal status disorders (subclinical, overt), taking into account the patient’s age. Diagnosis of endogenous subclinical hyperthyroidism is based solely on the results of laboratory tests, not clinical criteria. Endogenous subclinical hyperthyroidism is defined by the presence of sub-normal levels of thyroid-stimulating hormone with normal levels of free thyroxine, total triiodothyronine, and/or free triiodothyronine. There are two categories of endogenous subclinical hyperthyroidism: stage 1 – the level of thyroid-stimulating hormone is 0,1–0,39 mIU/l; stage 2 – the level of thyroid-stimulating hormone is <0.1 mIU/l. The levels of free thyroxine and free triiodothyronine, as a rule, are medium-high value at a subclinical level of thyroid hormone and can help differentiate between endogenous subclinical hyperthyroidism from overt hyperthyroidism. It is recommended to study the thyroid-stimulating hormone level as the first test for the diagnosis of subclinical hyperthyroidism. In identifying low levels of thyroid-stimulating hormone it is necessary to investigate the level of free thyroxine, free or bound triiodothyronine. Patients with primary sub-normal levels of thyroid-stimulating hormone with concentration of thyroid hormones in the upper limit or in normal range should be evaluated within 2-3 months. It is recommended to perform scintigraphy and possible 24-hour test the absorption of radioactive iodine if in patient with 2nd degree endogenous subclinical hyperthyroidism there is nodular goiter to determine treatment strategy. Ultrasonography with color Doppler can be informative for patients with endogenous subclinical hyperthyroidism and nodular goiter. Determining the level of antibodies to thyroid-stimulating hormone receptors can confirm the etiology of autoimmune-induced hyperthyroidism.

Download Full-text

Misleading results from immunoassays of serum free thyroxine in the presence of rheumatoid factor

Clinical Chemistry ◽

10.1093/clinchem/43.6.957 ◽

1997 ◽

Vol 43 (6) ◽

pp. 957-962 ◽

Cited By ~ 50

Author(s):

Anthony G W Norden ◽

Rodwin A Jackson ◽

Lorraine E Norden ◽

A Jane Griffin ◽

Margaret A Barnes ◽

...

Keyword(s):

Thyroid Hormone ◽

Rheumatoid Factor ◽

Equilibrium Dialysis ◽

Thyroid Stimulating Hormone ◽

Normal Serum ◽

Free Thyroxine ◽

Free Triiodothyronine ◽

Serum Free ◽

Serum Free Thyroxine ◽

Stimulating Hormone

Abstract A novel interference with measurements of serum free thyroxine (FT4) caused by rheumatoid factor (RhF) is described. We found misleading, sometimes gross, increases of FT4 results in 5 clinically euthyroid elderly female patients with high RhF concentrations. All 5 patients had high FT4 on Abbott AxSYM® or IMx® analyzers. “NETRIA” immunoassays gave misleading results in 4 of the 5 patients; Amerlex-MAB® in 2 of 4 patients; AutoDELFIA®in 2 of the 5; and Corning ACS-180® and Bayer Diagnostics Immuno 1® in 1 of the 5. BM-ES700® system results for FT4 in these women remained within the reference range. Results for serum T4, thyroid-stimulating hormone, free triiodothyronine, thyroid-hormone-binding globulin, and FT4 measured by equilibrium dialysis were normal in all 5 patients. Drugs, albumin-binding variants, and anti-thyroid-hormone antibodies were excluded as interferences. Addition to normal serum of the RhF isolated from each of the 5 patients increased the apparent FT4 (Abbott AxSYM). Screening of 83 unselected patients demonstrated a highly significant positive correlation between FT4 (Abbott AxSYM) and RhF concentrations. Discrepant, apparently increased FT4 with a normal result for thyroid-stimulating hormone should lead to measurement of the patient’s RhF concentration.

Download Full-text